Comparative Pharmacology
Head-to-head clinical analysis: FEXINIDAZOLE versus FUROXONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXINIDAZOLE versus FUROXONE.
FEXINIDAZOLE vs FUROXONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexinidazole is a nitroimidazole derivative that enters the parasite and inhibits DNA synthesis by forming reactive metabolites, leading to cell death. It is active against Trypanosoma brucei gambiense.
Furazolidone is a nitrofuran antimicrobial that inhibits bacterial monoamine oxidase and disrupts bacterial DNA synthesis by undergoing reduction by bacterial nitroreductases to reactive intermediates that cause DNA cross-linking and damage.
500 mg orally twice daily for 10 days for trichomoniasis; 2 g orally single dose for giardiasis.
100 mg orally four times daily
None Documented
None Documented
Approximately 8-12 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 1.5–2 hours; clinically, this supports dosing every 6 hours for sustained antibacterial effect.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal.
Primarily renal (approximately 65%) as unchanged drug; biliary/fecal excretion accounts for about 35%.
Category C
Category C
Antiprotozoal
Antibacterial/Antiprotozoal